The Latest Breaking News from Semdexa

Sorrento's Pain Company Reveals Final Results For SP-102 Data For Sciatica Pain Management

Sorrento Therapeutics Inc's (NASDAQ: SRNE) subsidiary Scilex Holding Company has announced final results from its SP-102 Phase 3 Pivotal Trial C.L.E.A.R. Program.  SP-102 (Semdexa) has received Fast Track status from the FDA.

Benzinga · Mar 18, 2022